샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731810

세계의 소화기내과 시장

Gastroenterology
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 401 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

소화기내과 세계 시장은 2030년까지 457억 달러에 이를 전망

2024년에 341억 달러로 추정되는 소화기내과 세계 시장은 2024-2030년의 분석 기간에 CAGR 5.0%로 성장하여 2030년에는 457억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 생물제제/바이오시밀러는 CAGR 3.8%를 나타내고, 분석 기간 종료시에는 113억 달러에 이를 것으로 예측됩니다. 제산제 부문의 성장률은 분석 기간중 CAGR 4.8%로 추정됩니다.

미국 시장은 93억 달러로 추정, 중국은 CAGR 7.7%로 성장 예측

미국의 소화기내과 시장은 2024년에 93억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 89억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.7%로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.5%와 4.9%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.2%를 보일 전망입니다.

세계의 소화기내과 시장 - 주요 동향과 성장 촉진요인 정리

소화기내과가 현대의학에서 주목받는 이유는?

소화기내과는 소화기관과 그 질환에 초점을 맞춘 의학의 한 분야로, 전 세계적으로 소화기 질환의 유병률이 증가함에 따라 현대 의료에서 점점 더 중요한 분야가 되고 있습니다. 과민성 대장 증후군(IBS), 위식도 역류질환(GERD), 크론병 및 궤양성 대장염과 같은 염증성 장질환(IBD), 비알코올성 지방간질환(NAFLD)과 같은 간질환의 유병률 증가로 인해 소화기내과에 대한 전문적 치료에 대한 수요가 증가하고 있습니다. 인구 고령화, 식습관 변화, 소화기 건강에 대한 인식 증가, 비만 및 당뇨병과 같은 질환의 세계적 증가 등의 요인이 소화기 질환의 부담 증가에 기여하고 있습니다. 또한, 환경적 요인과 유전적 요인이 소화기 질환의 주요 원인으로 인식되고 있으며, 소화기내과는 이러한 질환의 병인과 치료법을 이해하는 데 있어 더욱 적절한 분야로 인식되고 있습니다. 그 결과, 소화기내과는 예방적 건강 관리에 필수적인 분야가 되었으며, 조기 진단과 조기 관리가 환자의 예후를 개선하는 데 있어 매우 중요해졌습니다. 진단, 치료 및 개인 맞춤형 의료에 대한 관심이 높아짐에 따라 소화기내과는 현대 의학에서 흥미롭고 빠르게 진화하는 분야가 되었으며, 점점 더 많은 의료진과 연구자들이 이 분야에 관심을 기울이고 있으며, 점점 더 많은 세계 건강 문제를 해결하기 위해 이 분야에 집중하고 있습니다.

기술의 발전은 소화기내과 진료에 어떤 변화를 가져오고 있는가?

기술의 발전은 소화기내과 분야를 극적으로 변화시켜 진단의 정확성과 치료 효과를 크게 향상시켰습니다. 영상 진단에서는 고화질 내시경, 캡슐 내시경, 공초점 레이저 내시경(CLE)의 개발로 소화관 이상을 조기에 발견할 수 있는 능력이 향상되었습니다. 예를 들어, 캡슐 내시경 검사는 소화관 전체, 특히 기존에는 평가가 어려웠던 소장을 비침습적으로 시각화할 수 있습니다. 또한, 바이오마커와 분자 검사의 발전으로 보다 정확한 진단과 맞춤형 치료 계획이 가능해졌습니다. 특히 대장암의 경우, 유전자 검사는 위험 요인을 파악하고 치료법을 개별화하는 데 도움이 됩니다. 인공지능(AI)은 특히 내시경 영상 및 환자 데이터 분석에서 사람이 발견하기 어려운 패턴을 식별하기 위해 소화기내과에서 중요한 역할을 하고 있으며, AI 알고리즘은 영상 및 검사 결과의 미묘한 변화를 식별하여 소화기암 및 염증성 질환을 조기에 발견할 수 있도록 돕고 있습니다. 조기 발견을 지원할 수 있습니다. 또한, 내시경 초음파(EUS), 내시경 역행성 담관 췌관 조영술(ERCP)과 같은 최소침습적 기술의 사용으로 기존 수술적 방법에 비해 환자의 회복 시간 및 합병증 위험이 크게 감소하고 있습니다. 이러한 기술 혁신은 환자의 예후를 개선하고, 치료의 정확성을 높이며, 소화관 질환의 조기 발견과 효과적인 관리를 가능하게 합니다.

소화기내과 시장의 성장을 가속하는 주요 요인은?

소화기내과 시장은 고령화, 라이프스타일 변화, 위장 건강에 대한 인식 증가 등 여러 촉진요인으로 인해 크게 성장하고 있습니다. 세계 인구의 고령화에 따라 대장암, 간질환, 기능성 위장장애 등 고령층에서 많이 발생하는 위장질환의 발생률이 높아지고 있습니다. 또한, 식습관 장애, 운동 부족, 높은 스트레스 등 생활습관이 비만, GERD, IBD 등의 질환 증가로 이어지고 있으며, NAFLD, 위식도역류질환 등의 질환과 밀접한 관련이 있는 비만 유병률 증가는 특히 선진국을 중심으로 전 세계적인 건강 위기로 대두되고 있습니다. 생활습관과 위장 건강의 연관성에 대한 인식이 높아지면서 예방 의료, 정기적인 검진, 소화기 질환 치료를 찾는 사람들이 늘어나고 있습니다. 대장암, C형 간염과 같은 질병에 대한 전 세계적인 인식이 높아진 것도 소화기내과 서비스에 대한 수요 증가에 기여하고 있습니다. 특히 대장암 검진 프로그램의 개발은 대장암의 발견율과 치료 성과의 향상으로 이어져 소화기내과 시장의 성장을 더욱 촉진하고 있습니다. 또한, 신흥국에서는 의료 접근성이 향상됨에 따라 소화기내과 서비스 이용 범위가 확대되고 있습니다. 전문 소화기 센터의 확대와 고급 진단 및 치료의 가용성 증가는 전 세계적으로 증가하는 소화기 질환의 부담에 대응하는 데 도움이 되고 있습니다.

소화기내과 시장 성장의 주요 촉진요인은?

소화기내과 시장의 성장은 기술 발전, 질병 유병률 증가, 환자 중심 진료에 대한 관심 증가 등 여러 요인에 의해 촉진되고 있습니다. 특히 IBD, 대장암, NAFLD와 같은 질환은 식습관 장애, 흡연, 좌식 생활습관 등 현대인의 생활습관 요인으로 인해 더욱 흔해지고 있습니다. 이러한 질병이 확산됨에 따라 이러한 질병을 관리하기 위한 전문의, 진단 및 치료에 대한 수요가 증가하고 있습니다. 또한, AI 지원 내시경 및 최소 침습 수술과 같은 진단 및 치료의 혁신은 소화기내과 시술과 관련된 정확성, 속도 및 환자 결과를 개선하고 있습니다. 소화기내과에 유전체학을 통합하는 것도 개인 맞춤형 의료와 소화기 질환의 표적 치료로 전환하면서 성장을 가속하고 있습니다. 예방의학에 대한 관심이 높아진 것도 큰 촉진제입니다. 대장암, 간염 및 기타 소화기 질환에 대한 검진 접근성이 개선됨에 따라 의료 시스템은 이러한 질환을 조기에 발견하여 보다 효과적인 치료와 생존율 향상으로 이어질 수 있습니다. 또한, 신흥 시장에서의 중산층 확대는 소화기내과 서비스의 세계 성장에 기여하고 있습니다. 공중보건 캠페인, 정부의 이니셔티브, 소화기 질환에 대한 인식을 높이기 위한 국제적인 노력은 소화기 질환에 대한 수요를 더욱 증가시키고 있습니다. 마지막으로, 장내 세균총과 위장 건강 및 전반적인 건강에서의 역할에 대한 관심이 높아지면서 새로운 연구와 치료 옵션이 생겨나면서 소화기내과가 의료 혁신의 최전선에 서게 되었습니다. 이러한 요인들이 복합적으로 작용하여 소화기내과 시장의 성장을 가속하고 전 세계 소화기 질환 환자들의 치료의 질을 향상시키고 있습니다.

부문

약물 유형(생물학적 제제/바이오시밀러, 제산제, 하제, 지사제, 항구토제, 항궤양제, 기타 약물 유형); 질병 유형(염증성 장 질환, 크론병, 궤양성 대장염, 과민성 대장 증후군, 위식도 역류 질환, 간 질환, 대장암, 기타 질병 유형); 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 예(주목 41개사)

  • AbbVie Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Ferring Pharmaceuticals
  • GI Alliance
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc
  • Novartis AG
  • Olympus Corporation
  • Pfizer Inc.
  • Salix Pharmaceuticals
  • Sanofi S.A.
  • Sebela Pharmaceuticals
  • Takeda Pharmaceutical Company

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.05

Global Gastroenterology Market to Reach US$45.7 Billion by 2030

The global market for Gastroenterology estimated at US$34.1 Billion in the year 2024, is expected to reach US$45.7 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Biologics / Biosimilars, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$11.3 Billion by the end of the analysis period. Growth in the Antacids segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.3 Billion While China is Forecast to Grow at 7.7% CAGR

The Gastroenterology market in the U.S. is estimated at US$9.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.9 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Gastroenterology Market - Key Trends & Drivers Summarized

Why Is Gastroenterology Becoming a Key Focus in Modern Medicine?

Gastroenterology, the branch of medicine focused on the digestive system and its disorders, has become an increasingly critical field in modern healthcare due to the rising prevalence of digestive diseases globally. The growing incidence of conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis, and liver diseases like non-alcoholic fatty liver disease (NAFLD) is propelling the demand for specialized care in gastroenterology. Factors such as aging populations, changes in dietary habits, increased awareness of digestive health, and the global rise in conditions like obesity and diabetes contribute to the growing burden of gastrointestinal disorders. Additionally, environmental and genetic factors are increasingly being recognized as major contributors to gastrointestinal diseases, making gastroenterology more relevant in understanding both the etiology and treatment of these conditions. As a result, gastroenterology has become an essential part of preventive healthcare, with early diagnosis and management being crucial for improving patient outcomes. Advances in diagnostics, treatments, and a growing emphasis on personalized medicine are making gastroenterology an exciting and rapidly evolving area of modern healthcare, with an increasing number of healthcare providers and researchers focusing on this field to address the growing global health challenge.

How Are Technological Advancements Transforming Gastroenterology Practices?

Technological advancements have dramatically transformed the field of gastroenterology, significantly improving both diagnostic accuracy and treatment effectiveness. In diagnostic imaging, the development of high-definition endoscopy, capsule endoscopy, and confocal laser endomicroscopy (CLE) has enhanced the ability to detect gastrointestinal abnormalities at earlier stages. For instance, capsule endoscopy allows for the non-invasive visualization of the entire gastrointestinal tract, particularly the small intestine, a traditionally difficult area to assess. Additionally, advancements in biomarkers and molecular testing are allowing for more accurate diagnosis and personalized treatment plans, particularly in the case of colorectal cancer, where genetic testing can help identify risk factors and tailor therapies. Artificial intelligence (AI) is also playing a growing role in gastroenterology, particularly in the analysis of endoscopic images and patient data to identify patterns that may be difficult for human practitioners to detect. AI algorithms can assist in early detection of gastrointestinal cancers, inflammatory diseases, and other conditions by identifying subtle changes in imaging and laboratory results. Furthermore, the use of minimally invasive techniques, such as endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), has significantly reduced patient recovery time and risk of complications compared to traditional surgical methods. These technological innovations are improving patient outcomes, enhancing treatment precision, and enabling earlier detection and more effective management of gastrointestinal disorders.

What Are the Key Factors Driving Growth in the Gastroenterology Market?

The gastroenterology market is experiencing significant growth due to several driving factors, including an aging population, lifestyle changes, and increasing awareness of gastrointestinal health. As the global population ages, there is a higher incidence of gastrointestinal diseases such as colorectal cancer, liver diseases, and functional gastrointestinal disorders, which are more common in older adults. Additionally, lifestyle factors such as poor diet, lack of exercise, and high stress levels have contributed to an increase in conditions like obesity, GERD, and IBD. The rising prevalence of obesity, which is closely linked to conditions like NAFLD and gastroesophageal reflux disease, is becoming a global health crisis, particularly in developed countries. As awareness of the connection between lifestyle and gastrointestinal health grows, more people are seeking preventive care, regular screenings, and treatments for digestive disorders. The rise in global awareness of conditions like colorectal cancer and hepatitis C has also contributed to the increasing demand for gastroenterology services. The development of screening programs, particularly for colorectal cancer, has led to higher detection rates and better outcomes, further driving the growth of the gastroenterology market. Additionally, increasing access to healthcare in emerging economies is expanding the reach of gastroenterology services, where rising middle-class populations are demanding better care for digestive disorders. The expansion of specialized gastroenterology centers and the growing availability of advanced diagnostics and treatments are helping to address the growing global burden of digestive diseases.

What Are the Primary Drivers Behind the Growth of the Gastroenterology Market?

The growth of the gastroenterology market is driven by several factors that combine advancements in technology, increasing disease prevalence, and a focus on patient-centered care. A key driver is the rising global prevalence of gastrointestinal diseases, particularly conditions like IBD, colorectal cancer, and NAFLD, which are more common due to modern lifestyle factors such as poor diets, smoking, and sedentary lifestyles. As these diseases become more prevalent, there is a greater demand for gastroenterology specialists, diagnostics, and treatments to manage these conditions. Additionally, technological innovations in diagnostics and treatments, such as AI-assisted endoscopy and minimally invasive surgeries, are improving the accuracy, speed, and patient outcomes associated with gastroenterology procedures. The integration of genomics into gastroenterology is also driving growth, as the field moves toward personalized medicine and targeted therapies for gastrointestinal diseases. The increasing focus on preventive care is another significant growth driver. With improved access to screenings for colorectal cancer, hepatitis, and other gastrointestinal diseases, healthcare systems can catch these conditions at earlier stages, leading to more effective treatment and improved survival rates. Moreover, the expanding middle class in emerging markets is contributing to the global growth of gastroenterology services, as more people seek specialized care for digestive disorders. Public health campaigns, government initiatives, and international efforts to raise awareness of gastrointestinal diseases are further fueling the demand for gastroenterology services. Finally, the growing interest in gut microbiota and its role in gastrointestinal health and overall well-being is sparking new research and treatment options, positioning gastroenterology at the forefront of medical innovation. Together, these factors are driving the expansion of the gastroenterology market and enhancing the quality of care for patients with digestive diseases worldwide.

SCOPE OF STUDY:

The report analyzes the Gastroenterology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, Other Drug Types); Disease Type (Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Ferring Pharmaceuticals
  • GI Alliance
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc
  • Novartis AG
  • Olympus Corporation
  • Pfizer Inc.
  • Salix Pharmaceuticals
  • Sanofi S.A.
  • Sebela Pharmaceuticals
  • Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Gastroenterology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Gastrointestinal Disorders Drives Demand for Gastroenterology Services and Treatments
    • Here's the Story: How Advancements in Endoscopic Technology Are Revolutionizing Gastroenterology Diagnostics
    • Rising Awareness of Digestive Health and Wellness Fuels Growth in Preventive and Diagnostic Gastroenterology Services
    • Technological Innovations in Minimally Invasive Procedures Expand Treatment Options for Gastrointestinal Disorders
    • Surge in Aging Populations Globally Increases the Need for Gastroenterology Care and Disease Management
    • Here's How the Growing Focus on Personalized Medicine is Shaping the Future of Gastroenterology Treatments
    • Rising Incidence of Inflammatory Bowel Diseases (IBD) and Celiac Disease Strengthens the Business Case for Specialized Care
    • Expanding Role of Telemedicine and Remote Monitoring Drives Access to Gastroenterology Services in Underserved Areas
    • Increasing Research and Clinical Trials in Microbiome and Gut Health Create New Opportunities for Therapeutic Advancements
    • Here's How Advances in Artificial Intelligence and Machine Learning are Revolutionizing Gastroenterology Diagnostics
    • Growing Demand for Targeted Therapies and Biologics in Treating Gastrointestinal Disorders Expands Treatment Options
    • Global Increase in Obesity and Lifestyle-Related Disorders Drives Growth in Gastroenterology-Based Disease Prevention
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gastroenterology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics / Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics / Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Biologics / Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Laxatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antidiarrheal Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antidiarrheal Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Antidiarrheal Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Antiulcer Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Antiulcer Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Antiulcer Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Irritable Bowel Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Irritable Bowel Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Gastroesophageal Reflux Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Gastroesophageal Reflux Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Inflammatory Bowel Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Crohn's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 86: China Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Gastroenterology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 134: UK Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Spain 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Russia 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Russia 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 158: Russia Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Russia Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Russia 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Gastroenterology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Australia 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Australia 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 188: Australia Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Australia Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Australia 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 191: India Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: India 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: India 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 197: India Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: India Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: India 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: South Korea 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: South Korea 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 206: South Korea Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: South Korea Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: South Korea 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Asia-Pacific Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Asia-Pacific 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Gastroenterology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Latin America 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Latin America 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Latin America 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 227: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Latin America Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Latin America 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Argentina 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Argentina 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 236: Argentina Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Argentina Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Argentina 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Brazil 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Brazil 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 245: Brazil Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Brazil Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Brazil 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Mexico 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Mexico 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 254: Mexico Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Mexico Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Mexico 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Latin America 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Latin America Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Latin America Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Latin America 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Gastroenterology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Middle East 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Middle East 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Middle East 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 275: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Middle East Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Middle East 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Iran 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Iran 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 284: Iran Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Iran Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Iran 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Israel 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Israel 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 293: Israel Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Israel Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Israel 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Saudi Arabia 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 302: Saudi Arabia Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Saudi Arabia Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Saudi Arabia 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: UAE 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: UAE 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 311: UAE Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: UAE Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: UAE 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Middle East 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 320: Rest of Middle East Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Middle East Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Middle East 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Africa 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Africa 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
    • TABLE 329: Africa Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Africa Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Africa 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제